QUARTERLY STATEMENT 9M|2025

January 1 to September 30, 2025

STRATEC REPORTS DEFINITIVE RESULTS FOR FIRST NINE MONTHS OF 2025

- Despite supply chain-induced interruption to production, consolidated sales at constant currency up 2.5% (nominal: +1.5%) to € 175.6 million in 9M/2025 (9M/2024: € 173.0 million)
- Scale effects and higher earnings contributions from the realization of high-margin development sales are expected to drive significantly more dynamic earnings momentum in the fourth quarter of 2025
- Ongoing great momentum and strong demand for system solution development cooperations; new partnerships initiated
- 2025 guidance: sales at constant currency expected at around previous year's level with adjusted EBIT margin at lower end of forecast corridor of 10.0% to 12.0%

Key figures[1]

€ 000s	9M|2025	9M|2024[2]	Change	Q3|2025	Q3|2024[2]	Change
Sales	175,588	172,958	+1.5% (cc: +2.5%)	56,998	60,267	-5.4% (cc: -3.4%)
Adjusted EBITDA	24,235	26,623	-9.0%	8,165	9,197	-11.2%
Adjusted EBITDA margin (%)	13.8	15.4	-160 bps	14.3	15.3	-100 bps
Adjusted EBIT	12,824	15,149	-15.3%	4,337	5,269	-17.7%
Adjusted EBIT margin (%)	7.3	8.8	-150 bps	7.6	8.7	-110 bps
Adjusted consolidated net income	7,104	8,434	-15.8%	2,126	2,831	-24.9%
Adjusted earnings per share (€)	0.58	0.69	-15.9%	0.17	0.23	-26.1%
Earnings per share (€)	0.34	0.39	-12.8%	0.13	0.06	+116.7%

bps = basis points
cc = constant currency

[1] To facilitate comparison, figures for 2025 have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and restructuring expenses). The figures for 2024 have additionally been adjusted to exclude one-off personnel expenses of € 1.7 million in connection with the departure of a member of the Board of Management.
[2] Restated pursuant to IAS 8.

BUSINESS PERFORMANCE

STRATEC increased its consolidated sales year-on-year by 2.5 % on a constant-currency basis (nominal: +1.5 %) to € 175.6 million in the first nine months of 2025 (9M/2024: € 173.0 million). Systems sales at constant currency virtually matched the previous year's level. Alongside start-up curves for new product launches remaining flatter than usual, the third quarter also brought supply chain interruptions in connection with trade policy tensions and thus delivery backlogs with some system lines. By contrast, the stabilization in demand for system lines which had seen disruptions in the wake of the COVID-19 pandemic continued apace. Constant-currency sales with Service Parts and Consumables fell slightly short of the previous year's high figure. In the third quarter of 2025, this division felt the effects of volatile order behavior and logistics optimization measures taken by customers to account for changeable global tariff restrictions. Conversely, sales with Development and Services showed double-digit percentage growth, benefiting from a high volume of development activities and numerous customer projects currently underway.

Adjusted EBIT amounted to € 12.8 million in the first nine months of 2025 (9M/2024: € 15.1 million). Compared with the previous year, the adjusted EBIT margin thus fell by 150 basis points from 8.8 % to 7.3 %. This was particularly due to product mix effects within the Systems operating division, as well as to a temporary dip in the share of high-margin Service Parts and Consumables in the third quarter of 2025. The margin performance was additionally held back by negative exchange rate effects.

Adjusted consolidated net income stood at € 7.1 million in the first nine months of 2025, compared with € 8.4 million in the previous year. Here, STRATEC witnessed a year-on-year improvement in its net financial expenses and an increase in its adjusted tax rate. Adjusted earnings per share (basic) amounted to € 0.58 (9M/2024: € 0.69).

Reconciliation of adjusted EBITDA, EBIT, and consolidated net income

The key earnings figures for the first nine months of 2025 have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and restructuring expenses). A reconciliation of the adjusted results with the unadjusted key earnings figures is presented below:

Reconciliation of adjusted EBITDA (€ 000s)

	9M/2025	9M/2024[1]
Adjusted EBITDA	**24,235**	**26,623**
Adjustments:		
Other[2]	-1,677	-2,052
EBITDA	**22,558**	**24,571**

[1] Restated pursuant to IAS 8. Further details can be found in the 2024 Annual Report.
[2] Including one-off advisory expenses, fees, and restructuring expenses

Reconciliation of adjusted EBIT (€ 000s)

	9M/2025	9M/2024[1]
Adjusted EBIT	**12,824**	**15,149**
Adjustments:		
PPA amortization	-2,309	-2,772
Other[2]	-1,677	-2,052
EBIT	**8,838**	**10,325**

[1] Restated pursuant to IAS 8. Further details can be found in the 2024 Annual Report.
[2] Including one-off advisory expenses, fees, and restructuring expenses

Reconciliation of adjusted consolidated net income (€ 000s)

	9M/2025	9M/2024[1]
Adjusted consolidated net income	**7,104**	**8,434**
Adjusted earnings per share in € (basic)	**0.58**	**0.69**
Adjustments:		
PPA amortization	-2,309	-2,772
Other[2]	-1,677	-2,052
Taxes	985	1,156
Consolidated net income	**4,103**	**4,766**
Earnings per share in € (basic)	**0.34**	**0.39**

[1] Restated pursuant to IAS 8. Further details can be found in the 2024 Annual Report.
[2] Including one-off advisory expenses, fees, and restructuring expenses

FINANCIAL GUIDANCE

As already communicated in the announcement published on October 30, 2025, STRATEC expects to witness temporary interruptions to the supply of input materials for some system lines in the fourth quarter of 2025. In particular, in connection with trade policy tensions supply chain interruptions have arisen for a specific type of magnet with impurities relating to export-restricted rare earths (share of rare earths in affected production batch: 0.1%). Against this backdrop, delivery backlogs already arose for system deliveries in the third quarter of 2025. STRATEC does not expect to receive sufficient quantities of input materials to make up for these delivery backlogs or for the production volumes originally planned for the fourth quarter of 2025. Furthermore, global tariff conflicts are leading to higher fluctuations in customers' order behavior and to associated logistics optimization measures. These particularly affect the Service Parts and Consumables division. In view of these factors, on October 30, 2025 the Board of Management decided to adjust its sales guidance for the 2025 financial year. STRATEC now expects its consolidated sales at constant currency to approximately match the previous year's figure. Despite the lower sales base hereby forecast and negative currency items, STRATEC confirmed the lower end of the forecast corridor of around 10.0% to 12.0% for its adjusted EBIT margin. The expected intra-year rise in profitability in the fourth quarter of 2025 is attributable to benefits of scale, efficiency measures, and higher earnings contributions from the realization of high-margin development sales.

Based on updated planning, STRATEC assumes that its investments in property, plant and equipment and intangible assets in the 2025 financial year will fall slightly short of the originally forecast range of a total of 8.0% to 10.0% of sales (2024: 7.1%).

PROJECTS AND OTHER DEVELOPMENTS

Together with its partners, in the third quarter of 2025 STRATEC once again made further scheduled progress with numerous development projects and paved the way for additional cooperation agreements. The increasing willingness shown by customers in recent months to reach decisions concerning cooperations in the Systems Development business continued. Among other aspects, STRATEC has observed growing demand for lifecycle transfers. Furthermore, customers are increasingly looking for partners who are able to assume full responsibility for design, production, and delivery for the entire product lifecycle. The background to this development involves reorganization measures and M&A activities at customers, as well as their strategic focus on products already established in the market. These factors are supplemented by changed market conditions and growing requirements in terms of materials procurement. Against this backdrop, STRATEC recently initiated a partnership for a well-established high-throughput product in the field of molecular diagnostics.

The third quarter of 2025 also saw the market launch of the P780, a next-generation analyzer system offered under the Diatron brand in the field of clinical chemistry. To address a wide range of target customers, the P780 was developed for medium to large laboratories, offering an innovative and scalable solution characterized by great reliability.

DEVELOPMENT IN PERSONNEL

Including personnel hired from temporary employment agencies and trainees, the STRATEC Group had a total of 1,420 employees as of September 30, 2025 (previous year: 1,462 employees). This corresponds to a reduction of 2.9 % compared with the previous year's reporting date and is to be viewed in connection with the continuation in 2025 of the measures taken to enhance efficiency and improve earnings.

CONSOLIDATED BALANCE SHEET
as of September 30, 2025

Assets

€ 000s	09.30.2025	12.31.2024
Non-current assets		
Goodwill	49,597	50,975
Other intangible assets	64,447	62,889
Right-of-use assets	12,914	15,180
Property, plant and equipment	64,771	65,065
Non-current financial assets	4,086	3,472
Non-current other receivables and assets	343	0
Non-current contract assets	23,170	20,859
Deferred taxes	3,922	3,116
	223,250	**221,556**
Current assets		
Inventories	126,389	121,818
Trade receivables	41,947	41,578
Current financial assets	1,617	1,563
Current other receivables and assets	6,898	7,951
Current contract assets	7,545	1,209
Income tax receivables	1,194	2,219
Cash	22,396	47,164
	207,986	**223,502**
Total assets	**431,236**	**445,058**

Shareholders' equity and debt

€ 000s	09.30.2025	12.31.2024
Shareholders' equity		
Share capital	12,158	12,158
Capital reserve	37,723	37,131
Revenue reserves	194,076	197,267
Treasury stock	-35	-35
Other equity	-3,844	-3,988
	240,078	**242,533**
Non-current debt		
Non-current financial liabilities	116,952	88,695
Current other liabilities	1,330	1,201
Non-current contract liabilities	2,112	343
Provisions for pensions	5,117	5,338
Provisions	156	190
Deferred taxes	15,908	16,412
	141,575	**112,179**
Current debt		
Current financial liabilities	15,290	45,565
Trade payables	14,418	18,447
Current other liabilities	9,351	10,369
Current contract liabilities	7,216	7,235
Provisions	622	760
Income tax liabilities	2,686	7,970
	49,583	**90,346**
Total shareholders' equity and debt	**431,236**	**445,058**

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the period from January 1 to September 30, 2025

€ 000s	01.01. – 09.30.2025	01.01. – 09.30.2024 Retrospectively adjusted[1]
Sales	175,588	172,958
Cost of sales	-130,331	-125,672
Gross profit	**45,257**	**47,286**
Research and development expenses	-7,012	-8,123
Sales-related expenses	-8,973	-9,992
General administration expenses	-18,992	-18,597
Income / Expenses from impairment of financial assets and contract assets	-614	-11
Other operating expenses	-4,752	-4,038
Other operating income	3,924	3,800
Earnings before interest and taxes (EBIT)	**8,838**	**10,325**
Financial income	154	275
Financial expenses	-3,140	-4,486
Other financial result	-179	88
Net financial result	**-3,165**	**-4,123**
Earnings before taxes (EBT)	**5,673**	**6,202**
Taxes on income	-1,570	-1,436
Consolidated net income	**4,103**	**4,766**
Items that may be subsequently reclassified to profit or loss:		
Currency translation differences from translation of foreign operations	142	-4,104
Other comprehensive income (OCI)	**142**	**-4,104**
Comprehensive income	**4,245**	**662**
Basic earnings per share in €	**0.34**	**0.39**
No. of shares used as basis (undiluted)	12,155,942	12,155,942
Diluted earnings per share in €	**0.34**	**0.39**
No. of shares used as basis (diluted)	12,155,942	12,157,875

[1] Restated pursuant to IAS 8. Further details can be found in the 2024 Annual Report.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the period from July 1 to September 30, 2025

€ 000s	01.01. – 09.30.2025	01.01. – 09.30.2024 Retrospectively adjusted[1]
Sales	56,998	60,267
Cost of sales	-43,696	-43,527
Gross profit	**13,302**	**16,740**
Research and development expenses	-1,587	-2,563
Sales-related expenses	-2,466	-3,140
General administration expenses	-6,004	-7,337
Income / Expenses from impairment of financial assets and contract assets	-196	-20
Other operating expenses	-622	-1,461
Other operating income	1,092	217
Earnings before interest and taxes (EBIT)	**3,519**	**2,436**
Financial income	33	5
Financial expenses	-1,056	-1,483
Other financial result	-117	89
Net financial result	**-1,140**	**-1,389**
Earnings before taxes (EBT)	**2,379**	**1,047**
Taxes on income	-878	-327
Consolidated net income	**1,501**	**720**
Items that may be subsequently reclassified to profit or loss:		
Currency translation differences from translation of foreign operations	1,690	-434
Other comprehensive income (OCI)	**1,690**	**-434**
Comprehensive income	**3,191**	**286**
Basic earnings per share in €	**0.13**	**0.06**
No. of shares used as basis (undiluted)	12,155,942	12,155,942
Diluted earnings per share in €	**0.13**	**0.06**
No. of shares used as basis (diluted)	12,155,942	12,157,686

[1] Restated pursuant to IAS 8. Further details can be found in the 2024 Annual Report.

CONSOLIDATED CASH FLOW STATEMENT
for the period from January 1 to September 30, 2025

€ 000s	01.01. – 09.30.2025	01.01. – 09.30.2024 Retrospectively adjusted[1]
I. Operations		
Consolidated net income (after taxes)	4,103	4,766
Depreciation and amortization	13,720	14,246
Current income tax expenses	3,023	1,513
Income taxes paid less income taxes received	-7,253	-171
Financial income	-154	-275
Financial expenses	3,140	4,486
Interest paid	-3,420	-4,542
Interest received	224	275
Other non-cash expenses	4,227	1,732
Other non-cash income	-2,046	-1,195
Change in net pension provisions through profit or loss	-252	-23
Change in deferred taxes through profit or loss	-1,453	-77
Profit (-) / loss (+) on disposals of non-current assets	13	74
Increase (-) / decrease (+) in inventories, trade receivables and other assets	-11,685	4,418
Increase (+) / decrease (-) in trade payables and other liabilities	-3,622	203
Cash flow from operating activities	**-1,435**	**25,430**
II. Investments		
Incoming payments from disposals of non-current assets		
• Property, plant and equipment	0	9
Outgoing payments for investments in non-current assets		
• Intangible assets	-5,671	-6,344
• Property, plant and equipment	-7,124	-5,997
• Financial assets	-580	-100
Cash flow from investing activities	**-13,375**	**-12,432**
III. Financing		
Incoming funds from taking up of financial liabilities	42,000	12,000
Outgoing payments for repayment of financial liabilities	-41,109	-16,388
Outgoing payments for repayment of lease liabilities	-2,568	-2,407
Dividend payments	-7,294	-6,687
Cash flow from financing activities	**-8,971**	**-13,482**
IV. Cash-effective change in cash (net balance I – III)	**-23,781**	**-484**
Cash at start of period	47,164	33,532
Impact of exchange rate movements	-987	60
Cash at end of period	**22,396**	**33,108**

[1] Restated pursuant to IAS 8. Further details can be found in the 2024 Annual Report.

FINANCIAL CALENDAR

11	11
11.07.2025 Quarterly Statement 9M|2025	**11.25.2025** German Equity Forum (Analyst Conference)

Subject to amendment.
Quarterly statements and half-year financial reports are neither audited nor subject to an audit review by the group auditor.

ABOUT STRATEC

STRATEC SE (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and life siences. Furthermore, the company offers complex consumables for diagnostic and medical applications. For its analyzer systems and consumables, STRATEC covers the entire value chain – from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange.

IMPRINT AND CONTACT

Published by
STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 7082 7916-0
info@stratec.com
www.stratec.com

Head of Investor Relations,
Sustainability & Corporate Communications
Jan Keppeler
Phone: +49 7082 7916-6515
j.keppeler@stratec.com

Notice

Forward-looking statements involve risks: This quarterly statement contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

This quarterly statement contains various disclosures that from an economic point of view are not required by the relevant accounting standards. These disclosures should be regarded as a supplement, rather than a substitute for the IFRS disclosures.

Apparent discrepancies may arise throughout this quarterly statement on account of mathematical rounding up or down in the course of addition.

This quarterly statement is available in both German and English. Both versions can be downloaded from the company's website at www.stratec.com. In the event of any discrepancies between the two, the German report is the definitive version.